JCR Pharmaceuticals Overview
- Year Founded
-
1975
- Status
-
Public
- Employees
-
985
- Stock Symbol
-
4552
- Investments
-
5
- Share Price
-
$3.09
- (As of Thursday Closing)
JCR Pharmaceuticals General Information
Description
JCR Pharmaceuticals Co Ltd is a drug manufacturing company proactively engaged in the research of enzymes and proteins. The company maintains a focus toward developing value-added treatment options to address unmet medical needs. JCR utilizes international partnerships as a component of its growth plan. The vast majority of JCR's revenue is generated from its pharmaceutical operations, followed by medical devices and laboratory equipment. A portion of the company's sales are derived from licensing agreements. It operates in a single segment which is Pharmaceutical Business.
Contact Information
Website
www.jcrpharm.co.jpCorporate Office
- 3-19 Kasuga-cho
- Ashiya, Hyogo 659-0021
- Japan
Corporate Office
- 3-19 Kasuga-cho
- Ashiya, Hyogo 659-0021
- Japan
JCR Pharmaceuticals Stock Performance
As of 12-Nov-2026, JCR Pharmaceuticals’s stock price is $3.09. Its current market cap is $377M with 122M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.09 | $3.11 | $2.74 - $5.27 | $377M | 122M | 824K | -$0.18 |
JCR Pharmaceuticals Financials Summary
As of 30-Sep-2026, JCR Pharmaceuticals has a trailing 12-month revenue of $247M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | 673,047 | 667,347 | 509,469 | 741,049 |
| Revenue | 247,363 | 267,501 | 216,868 | 296,706 |
| EBITDA | (2,802) | 40,458 | (16,833) | 72,088 |
| Net Income | (21,597) | 14,450 | (29,246) | 38,113 |
| Total Assets | 723,408 | 683,331 | 700,664 | 675,428 |
| Total Debt | 404,381 | 337,124 | 254,640 | 153,948 |
JCR Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
JCR Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
JCR Pharmaceuticals Patents
JCR Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| FR-3164355-A1 | Back protection equipment | Active | 11-Jul-2024 | ||
| FR-3164355-B1 | Back protection equipment | Active | 11-Jul-2024 | ||
| WO-2025229980-A1 | Lyophilized preparation | Pending | 01-May-2024 | ||
| WO-2025230000-A1 | Modified aav particles, method for producing same, related medicine, and production of same | Pending | 01-May-2024 | ||
| JP-2025027593-A | Method for treating retinal disease | Pending | 16-Aug-2023 |
JCR Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
JCR Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
JCR Pharmaceuticals Investments & Acquisitions (5)
JCR Pharmaceuticals’s most recent deal was a Joint Venture with AlliedCel Corporation. The deal was made on 03-Oct-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| AlliedCel Corporation | 03-Oct-2022 | Joint Venture | Biotechnology | ||
| Mycenax Biotech | 27-Jul-2022 | PIPE | Other Pharmaceuticals and Biotechnology | ||
| ArmaGen | 20-Apr-2020 | Merger/Acquisition | Drug Discovery | ||
| Sumitomo Pharma (Growject) | 01-Jul-2010 | Merger/Acquisition | Pharmaceuticals | ||
| ISS (Property and Casualty Insurance) | 01-Nov-2009 | Merger/Acquisition | Property and Casualty Insurance |
JCR Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
32.03 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
JCR Pharmaceuticals Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| JCR Europe | Leiden, Netherlands | 2022 |
JCR Pharmaceuticals FAQs
-
When was JCR Pharmaceuticals founded?
JCR Pharmaceuticals was founded in 1975.
-
Where is JCR Pharmaceuticals headquartered?
JCR Pharmaceuticals is headquartered in Ashiya, Japan.
-
What is the size of JCR Pharmaceuticals?
JCR Pharmaceuticals has 985 total employees.
-
What industry is JCR Pharmaceuticals in?
JCR Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is JCR Pharmaceuticals a private or public company?
JCR Pharmaceuticals is a Public company.
-
What is JCR Pharmaceuticals’s stock symbol?
The ticker symbol for JCR Pharmaceuticals is 4552.
-
What is the current stock price of JCR Pharmaceuticals?
As of 12-Nov-2026 the stock price of JCR Pharmaceuticals is $3.09.
-
What is the current market cap of JCR Pharmaceuticals?
The current market capitalization of JCR Pharmaceuticals is $377M.
-
What is JCR Pharmaceuticals’s current revenue?
The trailing twelve month revenue for JCR Pharmaceuticals is $247M.
-
What is JCR Pharmaceuticals’s annual earnings per share (EPS)?
JCR Pharmaceuticals’s EPS for 12 months was -$0.18.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
